Answer
Letermovir (Prevymis) is indicated for prophylaxis of CMV reactivation and disease in CMV-seropositive adult and paediatric recipients of an allogeneic haematopoietic stem cell transplant who weigh at least 15 kg.
Sources for this answer
- PREVYMIS 240 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.1 Therapeutic Indications · Version 14Document updated
Sources checked